Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway-Reference-Cited by-同舟云学术

Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway

Published:2021-08 Issue:8 Volume:11 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical and Translational Medicine

Author:

Zhang Yi¹²³^ORCID,He Long‐Jun⁴,Huang Lin‐Lin¹⁵,Yao Sheng¹,Lin Nan²,Li Ping¹,Xu Hui‐Wen¹,Wu Xi‐Wen³,Xu Jian‐Liang²,Lu Yi²,Li Yan‐Jie²,Zhu Sen‐Lin¹

Affiliation:

1. Department of Gastroenterology and Hepatology, the First Affiliated Hospital Sun Yat‐sen University No.58 Zhongshan 2nd Road Guangzhou 510630 China

2. Department of Hepatobiliary surgery, the Third Affiliated Hospital Sun Yat‐sen University No.600 Tian he Road Guangzhou 510630 China

3. Department of Hepatic surgery, the First Affiliated Hospital Sun Yat‐sen University No.58 Zhongshan 2nd Road Guangzhou 510080 China

4. State Key Laboratory of Oncology in South China Cancer Center Sun Yat‐sen University No.651 Dongfeng Road East Guangzhou 510060 China

5. Department of Gastroenterology and Hepatology Guangdong Provincial People's Hospital/Guangdong Academy of Medical Sciences No.106 Zhongshan 2nd Road Guangzhou 510080 China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Guangdong Province

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.503

Reference76 articles.

1. Cancer statistics, 2018

2. Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer